ArticleEuropean journal of nuclear medicine and molecular imaging2020
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Pooled it
- The performance ofAsian journal of andrologyPooled it
- Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review).International journal of oncology · 2026Review
- Review
- Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.European journal of nuclear medicine and molecular imaging · 2024Article
- Determining the optimal pharmacokinetic modelling and simplified quantification method of [European journal of nuclear medicine and molecular imaging · 2024Article
- Combined whole-body dynamic and static PET/CT with low-dose [European journal of nuclear medicine and molecular imaging · 2024Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Is there more than meets the eye in PSMA imaging in prostate cancer with PET/MRI? Looking closer at uptake time, correlation with PSA and Gleason score.European journal of hybrid imaging · 2023Article
- Multiparametric dynamic whole-body PSMA PET/CT using [EJNMMI research · 2023Article
- Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [Molecular pharmaceutics · 2023Article
- Recurrent Prostate Cancer Diagnostics withDiagnostics (Basel, Switzerland) · 2022Review
- Phantom Validation of a Conservation of Activity-Based Partial Volume Correction Method for Arterial Input Function in Dynamic PET Imaging.Tomography (Ann Arbor, Mich.) · 2022Article
- Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-bodyEJNMMI research · 2022Article
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2022Article
- Article
- Pharmacokinetic studies of [European journal of nuclear medicine and molecular imaging · 2021Article
- Parameters predicting [EJNMMI research · 2021Article
- Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives.European journal of nuclear medicine and molecular imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAim of the present analysis is to investigate the biodistribution and pharmacokinetics of the recently clinically introduced radioligand
methodsTwenty-five (25) patients with PC biochemical relapse or progression (median age = 66.0 years) were enrolled in the analysis. The median PSA value was 1.2 ng/mL (range = 0.1-237.3 ng/mL) and the median Gleason score was 7 (range = 6-10). All patients underwent dynamic PET/CT (dPET/CT) scanning (60 min) of the pelvis and lower abdomen as well as whole-body PET/CT with
results15/25 patients were PET-positive. Plasma PSA values in the
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.